Patient characteristics
| Variable | n=84 |
| Female, n (%) | 53 (63.1) |
| Age in years, mean (SD) | 41.6 (14.7) |
| Smoker, n (%) | 10 (11.9) |
| Disease duration, mean (SD) | 12.3 (8.9) |
| Previous resection, n (%) | 43 (51.0) |
| Location, n (%) | |
| L1 | 28 (33.7) |
| L2 | 14 (16.9) |
| L3 | 38 (45.8) |
| L4 | 3 (3.6) |
| Behaviour, n (%) | |
| B1 | 37 (44.6) |
| B2 | 27 (32.5) |
| B3 | 19 (22.9) |
| P | 21 (25.0) |
| Previous biologics, n (%) | |
| Infliximab | 69 (82.1) |
| Adalimumab | 69 (82.1) |
| Golimumab* | 6 (7.1) |
| Certolizumab* | 4 (4.8) |
| Vedolizumab | 36 (42.9) |
| Vedolizumab and anti-TNF | 35 (41.7) |
| Nil | 2 (2.4) |
| Combination therapy, n (%) | 39 (46.4) |
| Current treatment, n (%) | |
| 6-MP | 5 (6.0) |
| Azathioprine | 14 (16.7) |
| Methotrexate | 19 (22.6) |
| Prednisolone | 6 (7.1) |
| CRP, mean (SD) | 14.7 (21.1) |
| Calprotectin, mean (SD) | 1343 (1747) |
| PGA, n (%) | |
| Mild | 11 (13.3) |
| Moderate | 39 (47.0) |
| Severe | 33 (39.8) |
*Off-licence for anti-TNF responsive disease via individual funding requests.
PGA, physician's global assessment.